Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease

Suggala Ramya Shri ¹ , Suman Manandhar ¹ , Yogendra Nayak ¹ , K Sreedhara Ranganath Pai ¹ *

Cited by CrossRef: 11

1- Shri S, Nayak Y, Ranganath Pai S. Molecular docking studies and molecular dynamic simulation analysis: To identify novel ATP-competitive inhibition of Glycogen synthase kinase-3β for Alzheimer’s disease. F1000Res. 2024;13:773 [Crossref]

2- Pal C. Mitochondria-targeting by small molecules against Alzheimer's disease: A mechanistic perspective. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2025;1871(3):167617 [Crossref]

3- Góral I, Wichur T, Sługocka E, Godyń J, Szałaj N, Zaręba P, Głuch-Lutwin M, Mordyl B, Panek D, Więckowska A. Connecting GSK-3β Inhibitory Activity with IKK-β or ROCK-1 Inhibition to Target Tau Aggregation and Neuroinflammation in Alzheimer’s Disease—Discovery, In Vitro and In Cellulo Activity of Thiazole-Based Inhibitors. Molecules. 2024;29(11):2616 [Crossref]

4- El‐Kadi R, AbdelKader N, Zaki H, Kamel A. Influence of β‐catenin signaling on neurogenesis in neuropsychiatric disorders: Anxiety and depression. Drug Development Research. 2024;85(1) [Crossref]

5- Bayraktar G, Alptüzün V. Recent Molecular Targets and their Ligands for the Treatment of Alzheimer Disease. CTMC. 2024;24(28):2447 [Crossref]

6- Jitendra Joshi N, Raja Sekhar Reddy A. Navigating the GSK-3β inhibitors as versatile multi-target drug ligands in Alzheimer’s disease intervention – A comprehensive review. Results in Chemistry. 2024;7:101500 [Crossref]

7- Shri S, Nayak Y, Ranganath Pai S. Molecular docking studies and molecular dynamic simulation analysis: To identify novel ATP-competitive inhibition of Glycogen synthase kinase-3β for Alzheimer’s disease. F1000Res. 2024;13:773 [Crossref]

8- Thawabteh A, Ghanem A, AbuMadi S, Thaher D, Jaghama W, Karaman D, Karaman R. Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease. Molecules. 2024;29(21):5131 [Crossref]

9- Turkistani A, Al-kuraishy H, Al-Gareeb A, Albuhadily A, Alexiou A, Papadakis M, Elfiky M, Saad H, Batiha G. Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue. Mol Neurobiol. 2024;61(9):7092 [Crossref]

10- Ziętal K, Mirowska-Guzel D, Nowaczyk A, Blecharz-Klin K. Cnicus benedictus: Folk Medicinal Uses, Biological Activities, and In Silico Screening of Main Phytochemical Constituents. Planta Med. 2024;90(13):976 [Crossref]

11- Dunlap N, Friedland R, Cai L. Alzheimer's disease and low-dose radiation therapy: A new hope. Radiation Medicine and Protection. 2024;5(1):1 [Crossref]

12- Ansari M, Sahu S, Singh T, Singh S, Kaur P. Evolving significance of kinase inhibitors in the management of Alzheimer's disease. European Journal of Pharmacology. 2024;979:176816 [Crossref]

13- Sai Varshini M, Aishwarya Reddy R, Thaggikuppe Krishnamurthy P. Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer’s therapy. Journal of Drug Targeting. 2024;32(8):909 [Crossref]